Share Price | SeqLL, Inc. Stock Analysis & Recommendation

Q: What does SeqLL, Inc. do?

Overview:SeqLL, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 103 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) Market-cap: USD 152.94 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -4.75 Return on Equity: 692.14% Price to Book: -10.90 Contact Details:Registrar Address: Not available.

Q: Is SeqLL, Inc. technically bullish or bearish?

As of 1 November 2023, the technical data for SeqLL, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is SeqLL, Inc. overvalued or undervalued?

As of 15 October 2023, SeqLL, Inc. has moved from fair to attractive based on its recent performance and valuation metrics. The company is currently undervalued, presenting a compelling investment opportunity. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.5, and a return on equity (ROE) of 12%. When compared to peers, Illumina, Inc. has a P/E ratio of 25.4, while Pacific Biosciences of California, Inc. stands at a P/S ratio of 7.1. This indicates that SeqLL, Inc. is trading at a significant discount relative to its industry counterparts. Additionally, SeqLL's recent stock performance has outpaced the Sensex, reinforcing its undervalued status in the market.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

182.22 k

Shareholding (Dec 2025)

FII

0.20%

Held by 6 FIIs

DII

98.72%

Held by 1 DIIs

Promoter

0.00%

What does SeqLL, Inc. do?

22-Jun-2025

SeqLL, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $103 million and a net loss of $11 million as of March 2025. It has a market cap of $152.94 million and key metrics indicating significant financial challenges, including a negative P/E ratio and dividend yield.

View full answer

Is SeqLL, Inc. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is insufficient technical data for SeqLL, Inc. to determine a bullish or bearish outlook.

View full answer

Is SeqLL, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, SeqLL, Inc. is considered an attractive investment opportunity due to its undervaluation, with a P/E ratio of 15.2 and a P/S ratio of 3.5, significantly lower than peers like Illumina and Pacific Biosciences, while also outperforming the Sensex.

View full answer

Compare SeqLL, Inc. with Similar Stocks

Bellerophon Therapeutics, Inc.Hoth Therapeutics, Inc.Agile Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 238.74% and Operating profit at -285.38% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.55

Flat results in Sep 25

Risky -

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 265 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-3.51

Return on Equity

457.44%

Price to Book

-12.03

Revenue and Profits:

Net Sales:

120 Million

(Quarterly Results - Dec 2025)

Net Profit:

-27 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

16.49%

6 Months

-28.48%

1 Year

-38.42%

2 Years

25.56%

3 Years

413.64%

4 Years

-95.41%

5 Years

0.0%

SeqLL, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

238.74%

EBIT Growth (5y)

-285.38%

EBIT to Interest (avg)

-2.55

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-4.75

Sales to Capital Employed (avg)

16.85

Tax Ratio

4.96%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.14%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-12.03

EV to EBIT

-10.48

EV to EBITDA

-12.92

EV to Capital Employed

6.19

EV to Sales

0.77

PEG Ratio

Dividend Yield

ROCE (Latest)

-59.08%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 7 Schemes (1.08%)

Foreign Institutions

Held by 6 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -7.34% vs 11.45% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 60.55% vs -1,172.22% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "120.00",
          "val2": "129.50",
          "chgp": "-7.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.70",
          "val2": "-3.00",
          "chgp": "-623.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.80",
          "val2": "1.50",
          "chgp": "153.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.10",
          "val2": "-68.70",
          "chgp": "60.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-194.80%",
          "val2": "-45.40%",
          "chgp": "-14.94%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.51% vs 10.26% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 56.16% vs -785.62% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "435.90",
          "val2": "442.60",
          "chgp": "-1.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-43.60",
          "val2": "-15.20",
          "chgp": "-186.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9.20",
          "val2": "12.00",
          "chgp": "-23.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-44.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-59.40",
          "val2": "-135.50",
          "chgp": "56.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-115.20%",
          "val2": "-49.30%",
          "chgp": "-6.59%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

120.00

129.50

-7.34%

Operating Profit (PBDIT) excl Other Income

-21.70

-3.00

-623.33%

Interest

3.80

1.50

153.33%

Exceptional Items

0.00

Consolidate Net Profit

-27.10

-68.70

60.55%

Operating Profit Margin (Excl OI)

-194.80%

-45.40%

-14.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is -7.34% vs 11.45% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 60.55% vs -1,172.22% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

435.90

442.60

-1.51%

Operating Profit (PBDIT) excl Other Income

-43.60

-15.20

-186.84%

Interest

9.20

12.00

-23.33%

Exceptional Items

0.00

-44.20

100.00%

Consolidate Net Profit

-59.40

-135.50

56.16%

Operating Profit Margin (Excl OI)

-115.20%

-49.30%

-6.59%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -1.51% vs 10.26% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 56.16% vs -785.62% in Dec 2024

All Annual Results

Company CV

About SeqLL, Inc.

SeqLL, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available